Telix Pharmaceuticals Limited
https://telixpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Telix Pharmaceuticals Limited
Keeping Track: Orladeyo, Danyelza, Imcivree Bring CDER 2020 Novel Approval Count Even With Full-Year 2019
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Asia Deal Watch: CStone Partners With LegoChem On Novel ADC Candidate
Plus deals involving Lilly/Daiichi Sankyo, Humianigen/KPM Tech, Telix/China Grand, Appili/Fujifilm, BioInvent/CASI, Osotec/Adel, Neumentum/Nuance, Takeda/HemoShear and Quantum Genomics/Qilu.
Keeping Track: New Nucala Indication; BMS’ Ide-Cel Clears Filing Hurdle; First Applications From Telix And ADC Therapeutics
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Asia Deal Watch: ReVance Licenses Chinese Rights To Botox Competitor To Fosun
With Phase III data in 2,800 patients for reducing frown lines, ReVance anticipates filing RT002 for US approval in 2019. ABL licenses two bispecific antibody candidates to TRIGR, while Sun looks to expand in dermatology with Pola buyout.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
- Other Names / Subsidiaries
-
- ATLAB Pharma SAS
- Advanced Nuclear Medicine Ingredients (ANMI) SA
- Telix Japan
- TheraPharm GmbH